The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1757
June 22, 2026
View Complete Issue         Table of Contents 2019 
Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia
June 22, 2026 (Issue: 1757)
Auvelity (Axsome), an extended-release fixed-dose combination of dextromethorphan and bupropion that was approved by the FDA for treatment of major depressive disorder in 2022, has now been approved for treatment of agitation associated with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia
Article code: 1757b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.